Crizotnib or Xalkori: Helps 5 in 100 Lung Cancer Patients

Pfizer's Crizotinib, also trading as Xalkori, has been announced as being beneficial to 5 in 100 lung cancer patients.

Crizotinib caused tumours to shrink or stabilise in 90% of 82 patients carrying the ALK fusion gene. Tumours shrank at least 30% in 57% of people treated.

Most had adenocarcinoma, and had never smoked or were former smokers. They had undergone treatment with an average of three other drugs prior to receiving crizotinib, and only 10% were expected to respond to standard therapy.

They were given 250 mg Crizotinib twice daily for a median duration of six months. Approximately 50% of these patients suffered at least one side effect, such as nausea, vomiting, or diarrhea.

Some responses to crizotinib have lasted up to 15 month.

Read more on this story Here 

RTOG and Highly-focused stereotactic body radiation therapy (SBRT)

Highly-focused stereotactic body radiation therapy (SBRT) can eliminate the targeted tumor while avoiding treatment-related illness and may ultimately improve survival for patients with inoperable non-small cell lung cancer, according to early findings of a Radiation Therapy Oncology Group (RTOG) study published in the March, cancer-themed, issue of the Journal of the American Medical Association.

Stereotactic body radiation therapy (SBRT) is a noninvasive cancer treatment in which numerous small, highly focused, and accurate radiation beams are used to deliver potent doses in 1 to 5 treatments to tumour targets.

"The primary finding and perhaps most exciting aspect to this prospective study was the high rate of primary tumour control (97.6 percent at 3 years). Primary tumour control is an essential requirement for the cure of lung cancer.

Stereotactic body radiation therapy as delivered in RTOG 0236 provided more than double the rate of primary tumour control previous reported for conventional radiotherapy suggesting that this technique could provide a significant step forward in the battle against this type of lung cancer," said Robert Timmerman, MD, of the University of Texas Southwestern Medical Center, Dallas, principal investigator on the RTOG study.

Currently, patients with inoperable early stage lung cancer are generally offered conventional radiation treatment (most commonly given during 20-30 outpatient treatments) or observed without specific cancer therapy. However, study authors indicate that neither of these approaches achieves ideal outcomes.